RxDoctor Payments Data

Eric Schmidt, MD

Cardiovascular Disease · Charlotte, NCNPI 1922035773

Payments from drug & device makers

$7,640in general payments, 2019–2025

Across 75 payments — averaging $101.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$5K
  • Abbott$503
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$371
  • Novartis$255
  • Abiomed$183
  • Edwards Lifesciences$170
  • plus $838 from 11 others

What the payments were for

  • Consulting fees$4,50059%
  • Food & beverage$3,14041%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,640 in reported general payments places this provider in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$261,457
Medicare patients
1,843
Services billed
8,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban414$473,993
EntrestoSacubitril/Valsartan89$136,579
XareltoRivaroxaban52$80,626
Repatha SureclickEvolocumab64$44,101
FarxigaDapagliflozin Propanediol26$31,359
JardianceEmpagliflozin20$16,821
Praluent PenAlirocumab17$12,044
NexlizetBempedoic Acid/Ezetimibe14$8,527
Atorvastatin Calcium399$4,064
Metoprolol Succinate207$3,228
Ranolazine ErRanolazine36$3,159
Diltiazem 24hr Er (Cd)Diltiazem Hcl81$2,647
Ezetimibe81$2,495
Rosuvastatin Calcium206$2,105
Carvedilol171$1,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$473,993414 claims
NovartisEntresto$255$136,57989 claims
AstraZenecaFarxiga$28$31,35926 claims
Boehringer IngelheimJardiance$73$16,82120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →